NASDAQ:CDT CDT Equity Q4 2024 Earnings Report $2.86 -0.04 (-1.38%) As of 08/21/2026 04:00 PM Eastern ProfileEarnings HistoryForecast CDT Equity EPS ResultsActual EPS-$609,900.00Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/ACDT Equity Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ACDT Equity Announcement DetailsQuarterQ4 2024Date3/28/2025TimeAfter Market ClosesConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile CDT Equity Earnings HeadlinesCDTTW CDT Equity Inc. C/WTS 22/09/28(TO PUR COM)August 7, 2026 | seekingalpha.comCDT Equity Expands Convertible Note and Equity FinancingAugust 6, 2026 | tipranks.comMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up Amazon and Netflix under $3 per share in 2005. Now the chief investment strategist at The Oxford Club has identified three AI stocks he believes could be the most profitable investments of the next decade.August 23 at 1:00 AM | The Oxford Club (Ad)CDT Equity to Boost Stake in SarborgAugust 5, 2026 | finance.yahoo.comCDT Increases Stake in Sarborg following its Quantum Computing and Intellectual Property ExpansionAugust 3, 2026 | globenewswire.comCDT Equity Expands Stake in Sarborg Via WarrantsJuly 31, 2026 | tipranks.comSee More CDT Equity Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like CDT Equity? Sign up for Earnings360's daily newsletter to receive timely earnings updates on CDT Equity and other key companies, straight to your email. Email Address About CDT EquityConduit Pharmaceuticals Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. The company was founded in 2019 and is based in San Diego, California. Conduit Pharmaceuticals Limited is a subsidiary of Corvus Capital Limited.View CDT Equity ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 08/17 - 08/21Flash in the Pan or Sustained Rally Contender? 3 Momentum Stocks to WatchRoss Stores Just Flipped the Off-Price Retail Story After TJX's Marmaxx Miss3 Stocks Came Roaring Back—Now They’re Flashing Warning SignsMicrosoft's Sell-Off May Be a Gift, Not a WarningIs Palo Alto Networks Priced for Perfection Again as AI Security Demand Accelerates?Advance Auto Parts Plunged, But Its Turnaround Is Still Working Upcoming Earnings PDD (8/24/2026)Bank Of Montreal (8/25/2026)Bank of Nova Scotia (8/25/2026)Intuit (8/25/2026)Salesforce (8/26/2026)CrowdStrike (8/26/2026)NVIDIA (8/26/2026)Synopsys (8/26/2026)Canadian Imperial Bank of Commerce (8/27/2026)Royal Bank Of Canada (8/27/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
